As viral diseases continue to pose complex global health challenges, researchers are increasingly exploring therapies that target the host-cell mechanisms viruses rely on to replicate. In line with this evolving scientific approach, Mumbai-based Godavari Biorefineries has secured a patent from the Japan Patent Office (JPO) for its invention titled "Use of Compounds for Treating Viral Infections."
The grant provides protection for the second medical use of the company's lead compound MSP22 and its derivatives for antiviral applications through inhibition of VATPase
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways. The research is an extension of the company's broader push to strengthen its life sciences capabilities through Sathgen Therapeutics, its biotechnology initiative focused on turning scientific discoveries into new therapies.
The invention forms part of Godavari Biorefineries Limited’s expanding life sciences research programme and adds to its growing portfolio in pharmaceutical innovation. By targeting host-cell pathways linked to viral infections, the compounds may interfere with viral entry and replication.
Securing this patent in Japan represents another step in the company’s efforts to protect intellectual property for this antiviral molecule class in key global markets. As these compounds act on a host-cell mechanism rather than targeting a specific virus, the research could point toward a broader antiviral strategy spanning multiple viral families.
